Evidence map›Paper›PMID 41891719›Full record

ArticleAntimicrobial agents and chemotherapy2026

RNA Polymerase 1 inhibitors against African trypanosomes

Alexander V Cumming, Nathaniel P Nenortas, Elizabeth Nenortas, Rahul P Bakshi, Emily R Caton, Estefany Rios-Guzman, Mary E Barry, James C Barrow, Marikki Laiho, Theresa A Shapiro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alexander V Cumming *Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0009-0003-7907-7165
Nathaniel P Nenortas *Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Elizabeth NenortasDivision of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rahul P BakshiDivision of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Emily R CatonDivision of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Estefany Rios-GuzmanDivision of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Mary E BarryDivision of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
James C BarrowDepartment of Pharmacology, Lieber Institute for Brain Development, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Marikki LaihoDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Theresa A ShapiroDivision of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-6823-7536

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Essential PK/PD relationships of antimalarial drugsR01AI095453 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SHAPIRO, THERESA A · 2012 to 2024
$4.8M
Blue One Biosciences LLCLieber Institute for Brain DevelopmentNCI NIH HHS P30 CA006973NIAID NIH HHS R01 AI095453NIH HHS P30CA006873NIH HHS R01AI095453
6 · The paper itself

Abstract

Therapy of human African trypanosomiasis, fatal if not treated, has been greatly improved by orally available and safer fexinidazole, but reliable cure of late-stage central nervous system (CNS) infection remains a challenge. African trypanosomes are unique among eukaryotes in having an RNA Polymerase 1 that transcribes not only rRNA but also mRNA that encodes the abundant variable surface glycoprotein (VSG) that coats the cell membrane of bloodstream-form parasites and allows them to evade host immune defenses. RNA Pol 1 inhibitor BMH-21, an intercalator not associated with DNA damage and a lead for new cancer therapy, has reported activity against the synthesis of rRNA and VSG mRNA in

Indexed as

Enzyme InhibitorsQuinazolinesRNA Polymerase ITrypanocidal AgentsTrypanosoma brucei bruceiTrypanosomiasis, AfricanAnimalsFemaleMiceEnzyme InhibitorsQuinazolinesRNA Polymerase ITrypanocidal AgentsBMH-21BOB-42hollow fiber model systeminhibitorsLI-623PK-PDRNA Polymerase 1Trypanosoma brucei bruceitrypanosomiasis

Identifiers

PMID41891719
PMCPMC13140157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.